clinical / clinicalBone Marrow Transplant

Nicolaus Kröger

尼古劳斯·克勒格尔

🏢University Medical Center Hamburg-Eppendorf(汉堡-埃彭多夫大学医学中心)🌐Germany

Head, Department of Stem Cell Transplantation干细胞移植科主任

h-index

Key Papers

Awards

Key Contributions

👥Biography 个人简介

Nicolaus Kröger leads the stem cell transplantation department in Hamburg and is the world's foremost authority on allogeneic HSCT for myelofibrosis, defining conditioning regimens, donor selection, and outcomes for this challenging indication.

🧪Research Fields 研究领域

Allogeneic HSCT for Myelofibrosis骨髓纤维化异基因移植

Myeloproliferative Neoplasms骨髓增殖性肿瘤

Reduced Intensity Conditioning减低强度预处理

GvHD ManagementGvHD管理

Donor Lymphocyte Infusion供者淋巴细胞输注

🎓Key Contributions 主要贡献

Allogeneic HSCT in Myelofibrosis

Established allogeneic SCT as the only curative therapy for myelofibrosis, developing and validating risk scoring systems, optimal conditioning strategies, and protocols for managing splenomegaly and engraftment challenges.

Ruxolitinib Bridging to Transplant

Pioneered the concept and clinical application of JAK inhibitor therapy as a bridge to transplantation in myelofibrosis, reducing spleen size and systemic inflammation to improve conditioning tolerance and engraftment.

Representative Works 代表性著作

[1]

Allogeneic stem cell transplantation for myelofibrosis: a consensus-based guideline of the European LeukemiaNet and EBMT

Leukemia (2015)

International consensus guidelines for HSCT in myelofibrosis co-authored by Kröger, adopted as standard worldwide.

[2]

Ruxolitinib as pretreatment before allogeneic stem cell transplantation for myelofibrosis

Biology of Blood and Marrow Transplantation (2019)

Prospective study demonstrating ruxolitinib bridging improves patient fitness and transplant outcomes in myelofibrosis.

🏆Awards & Recognition 奖项与荣誉

🏆German Society of Hematology and Oncology Award

🏆EBMT Myeloproliferative Neoplasm Working Party Founder

🏆European Hematology Association Outstanding Contribution Award

📄Data Sources 数据来源

Institution

Last updated: 2026-01-15 | All information from publicly available academic sources

Related Experts 相关专家

Hope S. Rugo

University of California, San Francisco (UCSF)

Antibody-Drug Conjugates in Metastatic Breast CancerASCENT Trial and Sacituzumab Govitecan

Maryam B. Lustberg

Yale School of Medicine / Yale Cancer Center

Cardiotoxicity of CDK4/6 Inhibitors and Endocrine TherapyCancer Treatment-Related Cardiovascular Disease

Sara M. Tolaney

Dana-Farber Cancer Institute / Harvard Medical School

T-DM1 and KATHERINE Trial in Residual Disease After Neoadjuvant TherapyTrastuzumab Deruxtecan (T-DXd) and DESTINY-Breast Trials

Carlos H. Barrios

PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil

CDK4/6 Inhibitors in Low- and Middle-Income Countries (LMIC)Global Breast Cancer Clinical Trials and Access

关注尼古劳斯·克勒格尔的研究动态

Follow Nicolaus Kröger's research updates

留下邮箱，当我们发布与 Nicolaus Kröger（University Medical Center Hamburg-Eppendorf）相关的新研究或访谈时，我们会通知你。

Explore More Experts

Discover the researchers shaping the future of cancer treatment

Browse All Experts Read Research Insights

International Translational Oncology Exchange